Company profile: Aragen Bioscience
1.1 - Company Overview
Company description
- Provider of preclinical contract research and development services specializing in recombinant cell line and hybridoma development, cell culture and protein purification process development and production, mammalian protein expression, primary and immortalized cell-based assays, in vivo models of human disease, custom immunological services, preclinical efficacy studies, and vivarium-based rodent studies including BSL-2 suites.
Products and services
- Protein Expression Services: Aragen delivers mammalian-based systems employing transient and stable cell line expression to produce recombinant proteins for various applications across preclinical research
- Cell Line Development (CLD): Aragen architects custom-engineered recombinant cell lines on CHO DG44 and CHO GS platforms to produce biologics, including monoclonal antibodies and recombinant proteins
- Protein Purification Services: Aragen offers chromatography-based, customized purification achieving high purity and biological activity with methods including tangential flow filtration and column chromatography for processing expressed proteins
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aragen Bioscience
Calyx
HQ: United States
Website
- Description: Provider of medical imaging, eClinical, and regulatory solutions and services to solve complex challenges in clinical research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calyx company profile →
CBPartners
HQ: United States
Website
- Description: Provider of strategy consulting services focused on strategic issues for multinational pharmaceutical, biopharmaceutical, and medical device companies, as well as governments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CBPartners company profile →
Vial
HQ: United States
Website
- Description: Provider of advanced programs for clinics to conduct lower-cost trials, specializing in computationally designed therapeutics and leveraging technology to automate clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vial company profile →
Uquifa
HQ: Spain
Website
- Description: Provider of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and custom synthesis services for the pharmaceutical industry. Operates three cGMP manufacturing sites (two in Spain, one in Mexico) inspected and approved by major pharmaceutical companies and regulatory authorities, including the US FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Uquifa company profile →
Adare Pharma Solutions
HQ: United States
Website
- Description: Provider of global technology-driven CDMO services spanning research, business and product development, formulation development (taste masking, customized release, patient-centered dosage forms), analytical services, clinical trial materials manufacturing and packaging (GMP and Non-GMP), commercial manufacturing, packaging, and logistical support, with delivery technologies including Diffucaps®, Microcaps®, and Optimμm®.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adare Pharma Solutions company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aragen Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aragen Bioscience
2.2 - Growth funds investing in similar companies to Aragen Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aragen Bioscience
4.2 - Public trading comparable groups for Aragen Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →